Immunome-Investor-Presentation-January-2026.pdf

1、1Immunome Corporate Presentation44th Annual J.P.Morgan Healthcare ConferenceJanuary 20262DisclosuresFor purposes of this notice,the“presentation”that follows shall mean and include the slides that follow,any oral presentation of the slides by members of management of Immunome,Inc.(“Immunome”)or any

2、person on its behalf,any question-and-answer session that follows that oral presentation,hard copies of this document and any materials distributed at,or in connection with,that presentation.References to“we,”“our,”and“us”refers to Immunome and its subsidiaries.This presentation shall not constitute

3、 an offer to sell or the solicitation of an offer to buy any Immunome securities.Forward-Looking StatementsStatements in this presentation that are not purely historical in nature are“forward-looking statements”within the meaning of the Private Securities Litigation Reform Act of 1995.We use words s

4、uch as“may,”“might,”“will,”“could,”“would,”“should,”“expect,”“intend,”“plan,”“vision,”“objective,”“anticipate,”“believe,”“estimate,”“predict,”“potential,”“continue,”“promising,”“projected,”“first step,”“ongoing,”or the negative of these terms,and similar words or expressions to identify these forwar

5、d-looking statements.These forward-looking statements include,but are not limited to,statements about:the expansion and advancement of Immunomes platform and pipeline and Immunomes approach;the expected benefits of Immunomes proprietary payload,HC74,and strategy related to Immunomes platform and pip

6、eline;assessments of the clinical efficacy,best-in-class potential,and potential commercial success of Immunomes product candidates,including IM-1021 and varegacestat;the potential of Immunomes current and future pipeline to produce first-in-class and/or best-in-class drugs;Immunomes expectations wi